Want to see ES:ECR full AI Analyst Report?
ECR Stock Chart & Stats
€3.43
€0.00(0.00%)
At close: 4:00 PM EST
€3.43
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€2.23 - €3.48
Previous CloseN/A
Volume8.56K
Average Volume (3M)68.83K
Market Cap
€317.28M
Enterprise Value€443.85M
Total Cash (Recent Filing)€96.03M
Total Debt (Recent Filing)€223.06M
Price to Earnings (P/E)―
Beta0.14
Next Earnings
Jul 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.27%
Share Statistics
EPS (TTM)-0.59
Shares Outstanding91,436,195
10 Day Avg. Volume92,838
30 Day Avg. Volume68,826
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.09
Price to Sales (P/S)0.50
P/FCF Ratio15.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.33
Revenue Forecast (FY)€662.80M
Bulls Say, Bears Say
Bulls Say
Cash Generation ResilienceErcros has demonstrated the ability to convert operations into cash repeatedly, with positive operating and free cash flow in 2025 and prior years. Durable cash conversion supports debt servicing, working-capital needs and reinvestment capacity even if earnings remain cyclical.
Moderate Absolute LeverageAlthough leverage has increased, total debt remained below equity in 2025, leaving a tangible capital cushion. This structural buffer preserves financial flexibility to manage cycles, negotiate supplier or creditor terms, and fund necessary maintenance capex without immediate solvency pressure.
Proven Upside In Favorable CyclesHistoric strong profitability in 2021–2022 shows the company’s asset base and product mix can deliver attractive margins when demand or prices improve. This structural capability implies earnings recoveries are feasible as market conditions normalize, supporting long-term return potential.
Bears Say
Deteriorating Profitability And RevenueA multi-year slide from strong profits to losses and declining revenue indicates persistent demand, pricing or mix pressures. Sustained weak top-line and margin erosion undermines internal funding, limits reinvestment and raises execution risk if structural market headwinds persist.
Rising Leverage And Shrinking EquityThe directional deterioration in the balance sheet—higher debt relative to equity and falling shareholder equity—reduces shock absorption. Over the medium term this can constrain strategic flexibility, raise financing costs, and magnify risk if margins or cash flow weaken further.
Volatile Cash Flow GenerationLarge swings in free cash flow complicate planning for capex, debt repayment and working-capital needs. Persistent volatility increases refinancing and operational risk, making it harder to rely on internal cash for growth or to smooth payouts during weaker demand periods.
Ercros SA News
ECR FAQ
What was Ercros SA’s price range in the past 12 months?
Ercros SA lowest stock price was €2.23 and its highest was €3.48 in the past 12 months.
What is Ercros SA’s market cap?
Ercros SA’s market cap is €317.28M.
When is Ercros SA’s upcoming earnings report date?
Ercros SA’s upcoming earnings report date is Jul 29, 2026 which is in 27 days.
How were Ercros SA’s earnings last quarter?
Ercros SA released its earnings results on May 20, 2026. The company reported -€0.266 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.266.
Is Ercros SA overvalued?
According to Wall Street analysts Ercros SA’s price is currently Overvalued.
Does Ercros SA pay dividends?
Ercros SA pays a Annually dividend of €0.096 which represents an annual dividend yield of 2.27%. See more information on Ercros SA dividends here
What is Ercros SA’s EPS estimate?
Ercros SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ercros SA have?
Ercros SA has 91,436,195 shares outstanding.
What happened to Ercros SA’s price movement after its last earnings report?
Ercros SA reported an EPS of -€0.266 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.146%.
Which hedge fund is a major shareholder of Ercros SA?
Currently, no hedge funds are holding shares in ES:ECR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ercros SA
Ercros, S.A. is a Spanish industrial group primarily engaged in the production and distribution of basic chemicals, intermediate chemical products, and pharmaceuticals. The company also extends its market reach through export activities. Its diverse operations are structured into three main divisions: Chlorine Derivatives, Intermediate Chemicals, and Pharmacy. The Chlorine Derivatives segment manufactures a broad spectrum of products, including ammonia, bioplastics, various caustic solutions (potash and soda), chlorine, chloroisocyanurates, dicalcium phosphate, dichloroethane, hydrochloric acid, hydrogen peroxide, potassium carbonate, PVC compounds, sodium chlorate and chlorite, sodium hypochlorite, and vinyl chloride monomers. These compounds serve as vital industrial intermediates, essential for applications such as purifying drinking and wastewater, maintaining swimming pools, bleaching paper and textiles, and formulating detergents, solvents, and strippers. They also find use in producing printing inks, animal feed, and cooling equipment. The Intermediate Chemicals division supplies products like formaldehyde, various glues and resins, molding powders, paraformaldehyde, pentaerythritol and dipentaerythritol, and sodium formate. These are crucial for manufacturing wood-based panels like chipboards, decorative laminates, and plywoods, as well as resins, paints, and varnishes for the furniture and decoration sectors. Furthermore, they are integral to producing electrical components such as plugs and switches, and contribute to household, sanitary, and packaging materials within the textile tanning industry. Ercros's Pharmacy segment focuses on developing and producing active pharmaceutical ingredients (APIs) and intermediate compounds. Its portfolio includes agents for various therapeutic areas, such as bacterial infections (e.g., azithromycin, clarithromycin, erythromycins, calcium and sodium fosfomycin, fosfomycin trometamol, fusidic acid), high cholesterol (amlodipine besylate), ulcers (famotidine), and fungal infections. With a rich history, Ercros, S.A. was established in 1817 and maintains its corporate headquarters in Barcelona, Spain.
Technical Analysis
Faes Farma
―
Grifols
―
LABORATORIO REIG JOFRE
―
Laboratorios Farmaceuticos Rovi
―
Repsol
―
Options Prices
Currently, No data available
---





